IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This study was conducted in order to evaluate the efficacy and safety of the cancer vaccine
IMA901 and GM-CSF as adjuvant in the treatment of advanced renal cell carcinoma.
Patients received vaccination with GM-CSF followed by IMA901 during the study period of 9
months. Patients received pre-treatment with a single i.v. infusion of cyclophosphamide prior
to the first vaccination.